Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Self-Reported Exposure to Neurotoxic Chemical Combinations in the Gulf War:A Cross-Sectional Epidemiologic Study
JAMA 227:231-237, 2591997., Haley,R.W.&Kurt,T.L., 1997
A Double-Blind, Controlled Trial of Intravenous Immunoglobulin in Patients with Chronic Fatigue Syndrome
Am J Med 89:561-568, 551-5531990., Lloyd,A.,et al, 1990
A Controlled Trial of Intravenous Immunoglobulin G in Chronic Fatigue Syndrome
Am J Med 89:554-560, 551-5531990., Peterson,P.K.,et al, 1990
Prevention of Falls Among the Elderly
NEJM 320:1055-1059, Tinetti,M.E.&Speechley,M., 1989
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Sweet Syndrome
Stat Pearls www.ncbi.nlm.gov, Sept, Goyal,V.P. & Holmes,H, 2022
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Tricyclic Antidepressants
Adams & Victors Principles of Neurology Chp 43, pg 1211, Ropper, A.H.,et al, 2014
Acute Symptomatic Seizures
The Neurologist 18:109-119, Beleza,P., 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Neuro-Sweets Disease
Pract Neurol 12:126-130, Maxwel,G.,et al, 2012
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Statin Induced Myopathy
BMJ 337:1159-1162, Sathasivam,S. &Lecky,B., 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Radiology 242:647-649, Kuo,P.H.,et al, 2007
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Syncope and Falls Due to Timolol Eye Drops
BMJ 332:960-961, Mller,M.E.,et al, 2006
Psychiatric Side Effects During Methysergide Treatment
JNNP 76:1037-1038, Cittadini,E. &Goadsby,P.J., 2005
Neurologic Oral Manifestations Caused by a New Formulation of Mirtazapine
Neurol 65:333-334, Kling,A.,et al, 2005
Central Nervous System Lymphoma Associated with Mycophenolate Mofetil in Lupus Nephritis
Lupus 14:910-913, Dasgupta,N.,et al, 2005
Use of Antihypertensive Agents in the Management of Patients with Acute Ischemic Stroke
Neurol 63:318-323, Lindenauer,P.K.,et al, 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Intrathecal Baclofen Withdrawal Mimicking Sepsis
J Emerg Med 24:423-427, Kao,L.W.,e tal, 2003
Transient Ischemic Attack and Stroke Associated with Sildenafil (Viagra) Use
Neurol 57:1730-1731, Morgan,J.C.,et al, 2001
Deterioration of Giant Cell Arteritis With Corticosteroid Therapy
Arch Neurol 57:581-584, Staunton,H.,et al, 2000
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Treatment of Postural Hypotension
JNNP 65:285-289, Mathias,C.J.&Kimber,J.R., 1998
Low Molecular Wt Heparinoid
ORG 10172 (Danaparoid) , & Outcome After Acute Ischemic Stroke, 10172 Acute Stroke Trtm (TOAST) Inve, t, JAMA 1272,1304,1998., 1998
Hemopericardium and Cardiac Tamponade after Thrombolysis for Acute Ischemic Stroke
Neurol 50:1857-1859, Kasner,S.E.,et al, 1998
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998